Trial Profile

Safety of Romiplostim (Nplate) in Patients Who Have Failed to Achieve Platelet Engraftment Following Umbilical Cord Blood Transplant

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Romiplostim (Primary)
Indications Cord blood stem cell transplant rejection; Stem cell engraftment
Focus Adverse reactions

Most Recent Events

05 Jun 2021 Status changed from active, no longer recruiting to completed.
01 Jun 2021 Results assessing safety profile and maximum tolerated dose (MTD) of romiplostim and to investigate whether romiplostim accelerates platelet recovery post-UCBT published in the Transplantation and Cellular Therapy
18 Apr 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com